Saddam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Saddam has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abrar Fahim
Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2 shared publications - Afsana Mimi
Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2 shared publications - Mohammad Ahsan Habib
Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2 shared publications - Mostofa Uddin Helal
Institute of Wheat Research, Key Laboratory of Sustainable Dryland Agriculture (Co-construction by Ministry and Province) Ministry of Agriculture and Rural Affairs, Shanxi Agricultural University, Linfen, China
2 shared publications - Saiful Islam
Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2 shared publications - Shamrat Kumar Paul
Department of Physics and Astronomy, College of Science, Clemson University, Clemson, SC 29634, USA
2 shared publications
Latest Publications
- Open Access
- 27 January 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-28
Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context
Apoptosis, also known as the programmed death of cells, is responsible for maintaining the homeostasis of tissues, and this function is carried out by caspases. The process of apoptosis is carried out via two distinct pathways: the extrinsic pathway, which is governed by death receptors, and the intrinsic pathway, also known as the mitochondrial pathway. The BCL-2 protein family encoded by the BCL-2 gene, located at the 18q21.33 chromosomal location, is in charge of regulating the intrinsic pathway, which is responsible for inducing cell death via the permeabilization of the mitochondrial membrane and the release of apoptosis-inducing components. The BCL-2 homology (BH1, BH2, BH3, BH4) domains of this family proteins are crucial for their functioning, and their common BH domains allow interactions between members of the same family and can also serve as indications of pro- or anti-apoptotic activity. A direct correlation may be shown between the overexpression of BCL-2 and the postponement of cell death. It has been determined that a change in the expression of BCL-2 is the root cause of a variety of malignancies, including lung, breast, melanoma, and chronic lymphocytic leukemia, multiple sclerosis, diabetes. In this review, we addressed the genetic information and structural homology of BCL-2 family members. Further, we elucidate the pro-apoptotic and anti-apoptotic roles of the family members. This review highlights the most recent developments in the BCL-2 protein family and presents evidence that targeting this family proteins may have a positive impact on the treatment of medical problems that are still underserved.
- 27 January 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-28
Open AccessEmerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context
Apoptosis, also known as the programmed death of cells, is responsible for maintaining the homeostasis of tissues, and this function is carried out by caspases. The process of apoptosis is carried out via two distinct pathways: the extrinsic pathway, which is governed by death receptors, and the intrinsic pathway, also known as the mitochondrial pathway. The BCL-2 protein family encoded by the BCL-2 gene, located at the 18q21.33 chromosomal location, is in charge of regulating the intrinsic pathway, which is responsible for inducing cell death via the permeabilization of the mitochondrial membrane and the release of apoptosis-inducing components. The BCL-2 homology (BH1, BH2, BH3, BH4) domains of this family proteins are crucial for their functioning, and their common BH domains allow interactions between members of the same family and can also serve as indications of pro- or anti-apoptotic activity. A direct correlation may be shown between the overexpression of BCL-2 and the postponement of cell death. It has been determined that a change in the expression of BCL-2 is the root cause of a variety of malignancies, including lung, breast, melanoma, and chronic lymphocytic leukemia, multiple sclerosis, diabetes. In this review, we addressed the genetic information and structural homology of BCL-2 family members. Further, we elucidate the pro-apoptotic and anti-apoptotic roles of the family members. This review highlights the most recent developments in the BCL-2 protein family and presents evidence that targeting this family proteins may have a positive impact on the treatment of medical problems that are still underserved.
- Open Access
Engineered BCL6 BTB Domain of the Bcl-2 Protein Family shows Dynamic Structural Behavior: Insights from Molecular Dynamics Simulations
Apoptosis is crucially regulated by the Bcl-6 protein, and mutations in this protein can have a significant impact on many malignancies. In this study, we used molecular dynamics simulations to examine the effects of specific mutations (Q8C, R67C, and N84C) in the crystal structure of the BCL6 BTB domain in a compound with pyrazole-pyrimidine ligand. We concentrated on comprehending the dynamics of these alterations and their possible effects on the emergence of cancer. To explore the structural and dynamic changes induced by these mutations, we performed in silico simulations using the GROMACS software suite (version 5.2, 2020.1) on Google Colab’s Tesla T4 GPU. The crystal structure of the BCL6 BTB domain in complex with the pyrazole-pyrimidine ligand (PDB ID: 5N20) served as the wild-type reference structure. Mutations were imposed using the Rotamer functions of Chimera. The simulations were carried out for a total duration of 20 ns using a time step of 2 femtoseconds (0.002 ps). The Trajectory profiles of the BCL6 BTB domain protein and its three mutations, Q8C, R67C and N84C, were shown to differ from each other. Based on the analysis of RMSD, RMSF, and Rg, it was determined that the mutant 2 (R67C) protein exhibited increased instability and greater flexibility. In contrast, mutant 3 (N84C) demonstrates a heightened level of compactness and greater stability compared to the remaining protein mutant. PCA also provides information regarding the structural dynamics of these mutants. In addition, the SASA and SASA autocorrelation provides a distinct view of the solvent accessibility of these proteins.
Open AccessEngineered BCL6 BTB Domain of the Bcl-2 Protein Family shows Dynamic Structural Behavior: Insights from Molecular Dynamics Simulations
Apoptosis is crucially regulated by the Bcl-6 protein, and mutations in this protein can have a significant impact on many malignancies. In this study, we used molecular dynamics simulations to examine the effects of specific mutations (Q8C, R67C, and N84C) in the crystal structure of the BCL6 BTB domain in a compound with pyrazole-pyrimidine ligand. We concentrated on comprehending the dynamics of these alterations and their possible effects on the emergence of cancer. To explore the structural and dynamic changes induced by these mutations, we performed in silico simulations using the GROMACS software suite (version 5.2, 2020.1) on Google Colab’s Tesla T4 GPU. The crystal structure of the BCL6 BTB domain in complex with the pyrazole-pyrimidine ligand (PDB ID: 5N20) served as the wild-type reference structure. Mutations were imposed using the Rotamer functions of Chimera. The simulations were carried out for a total duration of 20 ns using a time step of 2 femtoseconds (0.002 ps). The Trajectory profiles of the BCL6 BTB domain protein and its three mutations, Q8C, R67C and N84C, were shown to differ from each other. Based on the analysis of RMSD, RMSF, and Rg, it was determined that the mutant 2 (R67C) protein exhibited increased instability and greater flexibility. In contrast, mutant 3 (N84C) demonstrates a heightened level of compactness and greater stability compared to the remaining protein mutant. PCA also provides information regarding the structural dynamics of these mutants. In addition, the SASA and SASA autocorrelation provides a distinct view of the solvent accessibility of these proteins.
- Open Access
- 22 February 2023
- Published by MDPI AG in Preprints.org
Emerging Biomarkers and Potential Therapeutics of the BCL-2 Protein Family: The Apoptotic and Anti-Apoptotic Context
Apoptosis, also known as the programmed death of cells, is responsible for maintaining the homeostasis of tissues and this function is carried out by caspases. The process of apoptosis is carried out via two distinct pathways: the extrinsic pathway, which is governed by death receptors, and the intrinsic pathway, also known as the mitochondrial pathway. The BCL-2 protein family encoded by the BCL-2 gene, located at the 18q21.33 chromosomal location, is in charge of regulating the intrinsic pathway, which is responsible for inducing cell death via the permeabilization of the mitochondrial membrane and the release of apoptosis - inducing components. The BCL-2 homology (BH1, BH2, BH3, BH4) domains of this family proteins are crucial for their functioning and their common BH domains allow interactions between members of the same family and can also serve as indications of pro- or anti-apoptotic activity. A direct correlation may be shown between the overexpression of BCL-2 and the postponement of cell death. It has been determined that a change in the expression of BCL-2 is the root cause of a variety of malignancies, including lung, breast, melanoma, and chronic lymphocytic leukemia, Multiple Sclerosis, Diabetes. In this review, we discuss the therapeutic potential of regulating BCL-2 family connections and their relevance to health and disease.
- 22 February 2023
- Published by MDPI AG in Preprints.org
Open AccessEmerging Biomarkers and Potential Therapeutics of the BCL-2 Protein Family: The Apoptotic and Anti-Apoptotic Context
Apoptosis, also known as the programmed death of cells, is responsible for maintaining the homeostasis of tissues and this function is carried out by caspases. The process of apoptosis is carried out via two distinct pathways: the extrinsic pathway, which is governed by death receptors, and the intrinsic pathway, also known as the mitochondrial pathway. The BCL-2 protein family encoded by the BCL-2 gene, located at the 18q21.33 chromosomal location, is in charge of regulating the intrinsic pathway, which is responsible for inducing cell death via the permeabilization of the mitochondrial membrane and the release of apoptosis - inducing components. The BCL-2 homology (BH1, BH2, BH3, BH4) domains of this family proteins are crucial for their functioning and their common BH domains allow interactions between members of the same family and can also serve as indications of pro- or anti-apoptotic activity. A direct correlation may be shown between the overexpression of BCL-2 and the postponement of cell death. It has been determined that a change in the expression of BCL-2 is the root cause of a variety of malignancies, including lung, breast, melanoma, and chronic lymphocytic leukemia, Multiple Sclerosis, Diabetes. In this review, we discuss the therapeutic potential of regulating BCL-2 family connections and their relevance to health and disease.
- Open Access
- 26 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4972-4985
Potential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives
CCNs are a specific type of matricellular protein, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members, which exist only in vertebrates. The architecture of CCN proteins is multi-modular comprising four distinct modules. CCN Proteins achieve their primary functional activities by binding with several integrin7 receptors. The CCN family has been linked to cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, chondrogenesis, and wound healing, among other biological interactions. Breast cancer is the most commonly diagnosed cancer worldwide and CCN regulated breast cancer stands at the top. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. The pro-tumorigenic CCN1, CCN2, CCN3, and CCN4 may lead to human breast cancer, although the anti-tumorigenic actions of CCN5 and CCN6 are also present. Several studies have been conducted on CCN proteins and cancer in recent years. CCN1 and CCN3 have been shown to exhibit a dual nature of tumor inhibition and tumor suppression to some extent in quiet recent time. Pharmacological advances in treating breast cancer by targeting CCN proteins are also reported. In our study, we intend to provide an overview of these research works while keeping breast cancer in focus. This information may facilitate early diagnosis, early prognosis and the development of new therapeutic strategies.
- 26 November 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (6) , 4972-4985
Open AccessPotential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives
CCNs are a specific type of matricellular protein, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members, which exist only in vertebrates. The architecture of CCN proteins is multi-modular comprising four distinct modules. CCN Proteins achieve their primary functional activities by binding with several integrin7 receptors. The CCN family has been linked to cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, chondrogenesis, and wound healing, among other biological interactions. Breast cancer is the most commonly diagnosed cancer worldwide and CCN regulated breast cancer stands at the top. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. The pro-tumorigenic CCN1, CCN2, CCN3, and CCN4 may lead to human breast cancer, although the anti-tumorigenic actions of CCN5 and CCN6 are also present. Several studies have been conducted on CCN proteins and cancer in recent years. CCN1 and CCN3 have been shown to exhibit a dual nature of tumor inhibition and tumor suppression to some extent in quiet recent time. Pharmacological advances in treating breast cancer by targeting CCN proteins are also reported. In our study, we intend to provide an overview of these research works while keeping breast cancer in focus. This information may facilitate early diagnosis, early prognosis and the development of new therapeutic strategies.